Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PANTHEON: Aspirin-free strategy with ticagrelor in medically managed myocardial infarction
2025-525159-20-00Phase 3Authorised
- Sponsor
- Montréal Heart Institute
- Start
- Aug 2026
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 3, randomised, double-blind trial in myocardial infarction (MI) comparing Ticagrelor + aspirin (standard DAPT) with Ticagrelor + aspirin placebo (aspirin-free strategy) (2 arms). Primary endpoints: Primary bleeding endpoint and Primary patient-oriented ischemic clinical endpoint. Planned start Aug 2026; status: authorised.
02
Drugs
ticagrelor
03
Conditions
myocardial infarction (MI)
Beyond the preview
Go deeper on 2025-525159-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-525159-20-00.